System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Massimo Iacoviello is an expert in Cardiology at University of Foggia (Italy). As of October 2026, ScienceLeadR ranks Massimo Iacoviello in the top 1% of experts worldwide for Heart Failure. Massimo Iacoviello has authored 359 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 3 of them ongoing. SLR score: 1,155 (community average: 125). How the SLR is computed.

LeadR Profile

Massimo Iacoviello University of Foggia Italy
1 155 ScienceLeadR Reputation 1155

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Internal Medicine - Biochemistry - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2026
Source: PubMed

University of Foggia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 359

Citations

Citations: 15 399 1st author: 41 Last author: 56 Unique author: 2

Main journals

Eur Heart J Suppl 52
G Ital Cardiol (Rome) 37
Int J Cardiol 14
Endocr Metab Immune Disord Drug Targets 13
J Clin Med 13

Best Journals

Eur Heart J 3
Lancet Diabetes Endocrinol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The Multifaceted Role of the FLNC Gene in Hereditary Cardiomyopathies and Prognosis.
PMID 42793030 — genes, genomics, phenotype, prognosis, cardiomyopathies		Genes (Basel)20260
Response to Lu Li and colleagues.
PMID 42678397		Eur Heart J Cardiovasc Pharmacother20260
Strategies for preventing and reversing atrial cardiomyopathy (AtCM): current evidence, therapeutic targets, and future directions. A European Journal of Heart Failure expert consensus statement.
PMID 42617069 — fibrosis, heart failure, heart, atrial fibrillation, therapeutics, catheter ablation, cardiomyopathies		Eur J Heart Fail20260
Geographical and Ethnic Heterogeneity in Genetic Dilated Cardiomyopathies.
PMID 42511685 — cardiomyopathy, dilated, genetics, cardiomyopathies		Int J Mol Sci20260
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.
PMID 42469146 — cardiovascular diseases, adiposity, diet, obesity, therapeutics, overweight, education, semaglutide		Nutr Metab Cardiovasc Dis20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 3
Phase 3 3

By status:

Completed 2
Recruiting 2
Not yet recruiting 1
Unknown 1

By type:

Interventional 3
Observational 3

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase III Study to Investigate the Risk of Incident Heart Failure and Cardiovascular Death with Baxdrostat in Combination with Dapagliflozin in Participants with Increased Risk of Developing Heart Failure
2024-514506-32-00 — heart failure, heart		Phase 3Not yet recruiting2025
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure
2023-509706-30-00 — safety, heart failure, heart		Phase 3Recruiting2024
BRING UP 3 Heart Failure
NCT06279988 — heart failure, heart, heart failure, systolic, therapeutics		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS